NasdaqCM - Nasdaq Real Time Price USD

Fennec Pharmaceuticals Inc. (FENC)

6.48

+0.01

+(0.15%)

As of 1:28:59 PM EST. Market Open.

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and young people (1 month-17 years of age) ~ ~ Data from two open-label, randomized Phase 3 trials, SIOPEL 6 (pivotal) and the Clinical Oncology Group (COG) Protocol ACCL0431, demonstrated an approximate 50% reduction in the occurrence of cisplatin-induced ototoxicity in patients treated with cisplatin an

GlobeNewswire last month

FENC
+0.15%
Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ~ RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the early repayment of $13 million of the Company’s approximately $32 million outstanding convertible debt facility with Petricho

GlobeNewswire last month

FENC
+0.15%
Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the virtual H.C. Wainwright @ Home Fireside Chat Series taking place on Monday, December 16, 2024 at 11:00 a.m. ET. To access the live webcast, please visit: https://investors.fennecpharma.com/events-and-presentations/events. An archived replay of the webcast will be avai

GlobeNewswire last month

FENC
+0.15%
Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Fennec Pharmaceuticals ( NASDAQ:FENC ) Third Quarter 2024 Results Key Financial Results Revenue: US$6.97m (up 7.0% from...

Simply Wall St. 2 months ago

FENC
+0.15%
Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Fennec Pharmaceuticals Inc (FENC) reports increased sales and strategic initiatives, despite rising expenses and ongoing litigation challenges.

GuruFocus.com 2 months ago

FENC
+0.15%
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team with Chief Medical Officer, Chief Commercial Officer & Chief Strategy Officer Appointments ~ ~ Company Has Approximately $40 Million in Cash, Cash Equivalents, and Investment Securities Expected to Fund O

GlobeNewswire 2 months ago

FENC
+0.15%
Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursd

GlobeNewswire 2 months ago

FENC
+0.15%
Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%

Key Insights The considerable ownership by individual investors in Fennec Pharmaceuticals indicates that they...

Simply Wall St. 3 months ago

FENC
+0.15%
Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that it has strengthened its executive leadership team with the appointments of Pierre S. Sayad, PhD, M.S., as chief medical officer, Ter

GlobeNewswire 3 months ago

FENC
+0.15%
The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...

Simply Wall St. 3 months ago

FENC
+0.15%
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ETLocat

GlobeNewswire 4 months ago

FENC
+0.15%
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This Year

One thing we could say about the analysts on Fennec Pharmaceuticals Inc. ( NASDAQ:FENC ) - they aren't optimistic...

Simply Wall St. 5 months ago

FENC
+0.15%
Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

Fennec Pharmaceuticals ( NASDAQ:FENC ) Second Quarter 2024 Results Key Financial Results Revenue: US$7.26m (up 118...

Simply Wall St. 5 months ago

FENC
+0.15%
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call

Q2 2024 Fennec Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 5 months ago

FENC
+0.15%
Fennec Q2 Loss Stays Constant as Revenue More Than Doubles, Appoints Jeffrey Hackman as CEO

Fennec Q2 Loss Stays Constant as Revenue More Than Doubles, Appoints Jeffrey Hackman as CEO

PREMIUM
MT Newswires 5 months ago

FENC
+0.15%
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its f

GlobeNewswire 5 months ago

FENC
+0.15%
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Company to Also Participate in 2024 Wedbush PacGrow Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the U.S. financial markets on Tuesday, August 13, 2024. Management will host a conference call and webcast that day

GlobeNewswire 5 months ago

FENC
+0.15%
Update On Canada Stocks To Watch: Hut 8, Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

Update On Canada Stocks To Watch: Hut 8, Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

PREMIUM
MT Newswires 5 months ago

NVEI

FENC
+0.15%
EMICF
Canada Stocks To Watch: Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

Canada Stocks To Watch: Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

PREMIUM
MT Newswires 5 months ago

FENC
+0.15%
EMICF

AUMN
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr. Jeff Hackman as its Chief Executive O

GlobeNewswire 5 months ago

FENC
+0.15%

Performance Overview

Return	FENC	S&P/TSX Composite index
YTD	+5.19%	+4.94%
1-Year	-34.21%	+21.87%
3-Year	+46.61%	+24.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fennec Pharmaceuticals Inc. (FENC)

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Third Quarter 2024 Earnings: Misses Expectations

Fennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Individual investors account for 31% of Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) ownership, while hedge funds account for 30%

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company’s Next Stage of Growth

The past three years for Fennec Pharmaceuticals (NASDAQ:FENC) investors has not been profitable

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This Year

Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

Q2 2024 Fennec Pharmaceuticals Inc Earnings Call

Fennec Q2 Loss Stays Constant as Revenue More Than Doubles, Appoints Jeffrey Hackman as CEO

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Update On Canada Stocks To Watch: Hut 8, Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

Canada Stocks To Watch: Bitfarms; Emera; Energy Fuels; Fennec; Gran Tierra; Golden Minerals; Nuvei; Altius Renewable, Aura Minerals; 5N Plus, Green Thumb

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Performance Overview